Musculoskeletal Tumor Center, Peking University People's Hospital, Xicheng District, Beijing, China.
Spine (Phila Pa 1976). 2022 May 1;47(9):691-701. doi: 10.1097/BRS.0000000000004318. Epub 2021 Dec 27.
This was a retrospective study about sacral giant cell tumor of bone (GCTB).
This study aimed to investigate whether ultra-short course of neo-adjuvant denosumab treatment for sacral GCTB could (1) induce radiological and histological response? (2) Facilitate nerve-sparing surgery? (3) Achieve satisfactory oncological and functional outcomes?
Previous reports on long course of neo-adjuvant denosumab treatment for GCTB showed significant tumor response and a relatively high recurrent rate after curettage.
Sixty-six patients with sacral GCTB treated with neoadjuvant denosumab and nerve-sparing surgery were categorized into ultra-short course group (≤3 doses and operation within D21 since 1st dose, 41 patients) or conventional group (>3 doses or operation after D21 since 1st dose, 25 patients). The radiological and histological response, operative data, oncological and functional outcomes were compared.
The ultra-short course group demonstrated fewer doses of neo-adjuvant denosumab (mean: 2.1 vs. 4.8, P < 0.001) and shorter time to surgery (12.2 days vs. 72.3 days, P < 0.001). Similar patterns of radiological and histological response were observed in the two groups with less fibrosis and ossification in the ultra-short course group. The operative duration (199.9 min vs. 187.8 min, P = 0.364) and estimated blood loss (1552.4 mL vs. 1474.0 mL, P = 0.740) were comparable. Most (94.8%) of the patients received adjuvant denosumab. After a mean follow-up of 29.4 months, three cases (8.8%) and five cases (20.8%) showed local recurrence in each group (P = 0.255). The estimated recurrence-free survival (56.2 vs. 51.2 months, P = 0.210) and the functional status [Motor-Urination-Defecation scores: 25.9 vs. 25.7, P = 0.762] did not differ between the two groups.
Ultra-short course of neo-adjuvant denosumab for sacral GCTB could elicit radiological and histological responses as conventional course did. The less degree of fibrosis and ossification might facilitate nerve-sparing surgery and help to achieve satisfactory local control and functional status.Level of Evidence: 4.
这是一项关于骶骨巨细胞瘤(GCTB)的回顾性研究。
本研究旨在探讨超短疗程新辅助地舒单抗治疗骶骨 GCTB 是否能(1)诱导影像学和组织学反应?(2)有利于神经保留手术?(3)实现满意的肿瘤学和功能结果?
先前关于 GCTB 长疗程新辅助地舒单抗治疗的报告显示,肿瘤有明显的反应,但刮除术后复发率相对较高。
66 例接受新辅助地舒单抗和神经保留手术治疗的骶骨 GCTB 患者分为超短疗程组(≤3 剂,第 1 剂后 21 天内手术,41 例)或常规组(>3 剂或第 1 剂后 21 天内手术,25 例)。比较两组的影像学和组织学反应、手术数据、肿瘤学和功能结果。
超短疗程组新辅助地舒单抗的剂量较少(平均:2.1 剂比 4.8 剂,P<0.001),手术时间较短(12.2 天比 72.3 天,P<0.001)。两组影像学和组织学反应模式相似,超短疗程组纤维化和骨化程度较轻。手术时间(199.9 分钟比 187.8 分钟,P=0.364)和估计失血量(1552.4 毫升比 1474.0 毫升,P=0.740)相似。大多数(94.8%)患者接受了辅助地舒单抗治疗。平均随访 29.4 个月后,两组各有 3 例(8.8%)和 5 例(20.8%)出现局部复发(P=0.255)。估计无复发生存率(56.2 个月比 51.2 个月,P=0.210)和功能状态[运动-排尿-排便评分:25.9 分比 25.7 分,P=0.762]在两组间无差异。
超短疗程新辅助地舒单抗治疗骶骨 GCTB 可产生与常规疗程相似的影像学和组织学反应。较低程度的纤维化和骨化可能有利于神经保留手术,并有助于实现满意的局部控制和功能状态。
4 级。